These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 28482281)

  • 21. Renoprotection by blocking the RAAS in diabetic nephropathy--fact or fiction?
    Rossing P; Parving HH; de Zeeuw D
    Nephrol Dial Transplant; 2006 Sep; 21(9):2354-7; discussion 2357-8. PubMed ID: 16928724
    [No Abstract]   [Full Text] [Related]  

  • 22. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Renin-angiotensin system within the diabetic podocyte.
    Márquez E; Riera M; Pascual J; Soler MJ
    Am J Physiol Renal Physiol; 2015 Jan; 308(1):F1-10. PubMed ID: 25339703
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Renin angiotensin system (RAS) blockade and diabetic microvascular complications in the eye and kidney.
    Bilous R
    Prim Care Diabetes; 2008 Dec; 2(4):201-2. PubMed ID: 18760685
    [No Abstract]   [Full Text] [Related]  

  • 25. [Multilevel blockade of the renin-angiotensin-aldosterone system in the treatment of diabetic nephropathy].
    Fronczyk A; Majkowska L
    Przegl Lek; 2007; 64(2):81-5. PubMed ID: 17892038
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Beneficial impact on cardiovascular risk factors by dual blockade of the renin-angiotensin system in diabetic nephropathy.
    Jacobsen P; Parving HH
    Kidney Int Suppl; 2004 Nov; (92):S108-10. PubMed ID: 15485400
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is there benefit in dual renin-angiotensin-aldosterone system blockade? No, yes and maybe: a guide for the perplexed.
    Wong J
    Diab Vasc Dis Res; 2013 May; 10(3):193-201. PubMed ID: 23349369
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dual blockade of the renin-angiotensin system in diabetic nephropathy.
    Wade VL; Gleason BL
    Ann Pharmacother; 2004; 38(7-8):1278-82. PubMed ID: 15187210
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection.
    Zoja C; Corna D; Gagliardini E; Conti S; Arnaboldi L; Benigni A; Remuzzi G
    Am J Physiol Renal Physiol; 2010 Nov; 299(5):F1203-11. PubMed ID: 20719975
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transforming the Care of Patients with Diabetic Kidney Disease.
    Brosius FC; Cherney D; Gee PO; Harris RC; Kliger AS; Tuttle KR; Quaggin SE;
    Clin J Am Soc Nephrol; 2021 Oct; 16(10):1590-1600. PubMed ID: 34103350
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Progression of chronic renal insufficiency and its prevention using angiotensin converting enzyme inhibitors and angiotensin antagonists].
    Tesar V
    Vnitr Lek; 2003 May; 49(5):365-9. PubMed ID: 12908169
    [TBL] [Abstract][Full Text] [Related]  

  • 32. To RAS or not to RAS? The evidence for and cautions with renin-angiotensin system inhibition in patients with diabetic kidney disease.
    St Peter WL; Odum LE; Whaley-Connell AT
    Pharmacotherapy; 2013 May; 33(5):496-514. PubMed ID: 23576066
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Antihypertensive drug trials also reveal renoprotective effects].
    Kiss I
    Orv Hetil; 2013 May; 154(19):753-6. PubMed ID: 23649640
    [TBL] [Abstract][Full Text] [Related]  

  • 34. AT(1)-receptor blockade and the kidney: importance of non-ACE pathways in health and disease.
    Hollenberg NK
    J Hum Hypertens; 2002 Aug; 16 Suppl 3():S59-63. PubMed ID: 12140730
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recent changes in the landscape of combination RAS blockade.
    Epstein BJ; Smith SM; Choksi R
    Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
    [TBL] [Abstract][Full Text] [Related]  

  • 36. What is the role of direct renin inhibitors in the treatment of the hypertensive diabetic patient?
    de la Sierra A; Salazar J
    Adv Ther; 2011 Sep; 28(9):716-27. PubMed ID: 21809181
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intensified inhibition of renin-angiotensin system: a way to improve renal protection?
    Cravedi P; Ruggenenti P; Remuzzi G
    Curr Hypertens Rep; 2007 Nov; 9(5):430-6. PubMed ID: 18177592
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Angiotensin receptor blockers are associated with lower mortality than ACE inhibitors in predialytic stage 5 chronic kidney disease: A nationwide study of therapy with renin-angiotensin system blockade.
    Lin CC; Wu YT; Yang WC; Tsai MJ; Liu JS; Yang CY; Li SY; Ou SM; Tarng DC; Hsu CC
    PLoS One; 2017; 12(12):e0189126. PubMed ID: 29216260
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in diabetic kidney disease.
    Stanton RC
    Curr Diab Rep; 2013 Aug; 13(4):567-73. PubMed ID: 23653011
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease.
    Song JH; Cha SH; Lee HJ; Lee SW; Park GH; Lee SW; Kim MJ
    Nephrol Dial Transplant; 2006 Mar; 21(3):683-9. PubMed ID: 16330466
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.